The phrase "advance market commitment" is correct and usable in written English.
It is typically used in discussions about economic policies or strategies aimed at encouraging investment in specific markets or sectors, often related to public health or technology.
Example: "The government announced an advance market commitment to ensure that vaccines are available at affordable prices for low-income countries."
Alternatives: "pre-market agreement" or "early market pledge".
The countries involved in the Advance Market Commitment project decided to start with the pneumococcal vaccine because it could be brought to market quickly.
Dr. von Schoen-Angerer said that the multibillion-dollar cost of the project was straining GAVI's finances and that the success of the pneumococcal program should be evaluated before the advance market commitment strategy was tried for another vaccine.
However, under an arrangement called the Advance Market Commitment that was brokered by GAVI to entice vaccine companies to keep supplying poor countries, both companies get an additional $3.50 for the first six million shots.
Creative financing from multilateral donors (in the form of "advance market commitment") and non-governmental outfits such as the GAVI Alliance is spurring interest in the neglected diseases of the poor world.
The Advance Market Commitment is one of several new programs by wealthy nations intended to bring better health care to the developing world, particularly Africa, which is being devastated by H.I.V. and AIDS.
The first phase of the program, which is called the Advance Market Commitment, will cover the pneumococcal vaccine, a shot that is effective at preventing deadly pneumonia in children.
But pilot projects suggest the new policy may work.Yet another incentive-based approach bubbling up is Advance Market Commitments (AMC).
The agreement is the first example of GAVI's program called advance market commitments, in which donor money is used to essentially guarantee a market for vaccine companies if they undertake development of vaccines for poor countries, or if the companies agree to build extra capacity to supply those markets with an existing vaccine.
To encourage further discovery, researchers and policymakers are promoting new economic models of vaccine development, including prizes, tax incentives, and advance market commitments.
Pneumococcal conjugate vaccines, including PHiD-CV, are being introduced in African countries under the Advance Market Commitments for pneumococcal disease piloted by GAVI [ 2].
Over the last decade, a number of initiatives have emerged to address these issues including Advance Market Commitments, product development partnerships, patent pools, and prizes to reward innovation.
